Compare · AURA vs MRNA
AURA vs MRNA
Side-by-side comparison of Aura Biosciences Inc. (AURA) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AURA and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $18.94B, about 28.8x AURA ($656.5M).
- Over the past year, AURA is down 11.7% and MRNA is up 67.7% - MRNA leads by 79.4 points.
- MRNA has been more active in the news (15 items in the past 4 weeks vs 4 for AURA).
- MRNA has more recent analyst coverage (25 ratings vs 11 for AURA).
- Company
- Aura Biosciences Inc.
- Moderna Inc.
- Price
- $6.17-2.37%
- $46.26-3.11%
- Market cap
- $656.5M
- $18.94B
- 1M return
- -24.57%
- -12.33%
- 1Y return
- -11.73%
- +67.66%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 4
- 15
- Recent ratings
- 11
- 25
Aura Biosciences Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest AURA
- Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
- Officer Holles Natalie C. was granted 1,153,962 shares (SEC Form 4)
- Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- SEC Form S-8 filed by Aura Biosciences Inc.
- SEC Form SCHEDULE 13G filed by Aura Biosciences Inc.
- Aura Biosciences to Participate in Upcoming Investor Conferences
- Large owner Matrix Capital Management Company, Lp sold $39,044,987 worth of shares (6,922,870 units at $5.64) (SEC Form 4)
- SEC Form 10-Q filed by Aura Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Aura Biosciences Inc.
- Aura Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Latest MRNA
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Chief Legal Officer Klinger Shannon Thyme exercised 15,269 shares at a strike of $7.04, sold $173,550 worth of shares (3,471 units at $50.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 9% to 73,561 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability